Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Background: CAR T-cell therapy is a promising new treatment for blood cancers. During treatment, a person s T-cells are genetically changed to kill cancer cells. Researchers want to learn more about the effects of potential problems that may be associated with this treatment. We are specifically interested in learning if and how this treatment may affect the brain or your thinking skills. Objective: To learn if CAR T-cell therapy can affect how children and adults think, process, and remember things. Eligibility: People aged 5-35 who have blood cancer that has not responded to treatment, or the blood cancer has come back after treatment, and who will receive CAR T-cell therapy. Caregivers are also needed. All participants must be able to speak and read in English or Spanish. Design: Participants will be screened with a medical history. Information from participants medical records will be collected. Participants will take tests at home or at NIH to see how well they think, read, learn, remember, reason, and pay attention. The tests will be both computerized and paper/pencil. They will take less than 1 hour to complete. Participants and a parent/adult observer will complete a 5-minute Background Information Form and a checklist of nervous system symptoms. If participants are 5 years or older, they will participate in activities to test their ability to do different thinking tasks, like answer questions, complete puzzle patterns, and remember things. Participants and their caregivers will complete questions to see if they are having specific symptoms related to receiving CAR T-cells. The questions will assess their well-being and needs. The questions will take less than 1 hour to complete. Some tests and questions will be repeated at different time points in the study. Participation will last for up to 3 years.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek od 5 do 35 lat z rakiem krwi (białaczką lub chłoniakiem), który nie reaguje na leczenie lub wrócił po leczeniu
- •Pacjent będzie otrzymywać terapię CAR T w jednym z ośrodków badania
- •Pacjent musi mieć opiekuna dorosłego, który będzie uczestniczyć w badaniu
- •Możliwość mówienia i rozumienia języka angielskiego lub hiszpańskiego
- •Dostęp do komputera lub tabletu z kamerą i internetem do wykonania testów w domu
- •Pacjent lub rodzic musi móc podpisać zgodę na uczestnictwo w badaniu
✗ Disqualifies
- •Pacjent ma wcześniej zdiagnozowaną globalną niepełnosprawność intelektualną (na przykład zespół Downa)
Simplified criteria — AI translation
Trial details
- Minimum age
- 5 Years
- Last updated (source)
- July 17, 2026
- Sex
- No restrictions
Locations (3)
Children s Hospital of Los Angeles
Los Angeles, United States
National Institutes of Health Clinical Center
Bethesda, United States
Seattle Children s Hospital
Seattle, United States
Trial contact
NCI Ped LeukemiaLymph Cell Tx Tm
Pamela L Wolters, Ph.D.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/9/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.